Alnylam Pharmaceuticals Inc

Alnylam’s Nasdaq‑100 debut boosts visibility, liquidity, and investor confidence in its biopharma growth and pipeline.

Alnylam’s Nasdaq 100 debut, $508 price target, and strategic debt buy‑back signal a stronger capital structure poised to accelerate its RNAi pipeline and dominate the growing non‑opioid therapeutics market.

Alnylam’s siRNA strategy blends cutting‑edge RNA tech with value‑based pricing and HTA wins to capture high‑margin markets, from cardiology to Huntington’s disease.

Alnylam’s vutrisiran shows significant heart‑function gains in ATTR‑CA patients, supporting expedited FDA approval and a potential first‑line disease‑modifying therapy.

Alnylam Pharmaceuticals Inc. is poised to capitalize on the growing rare-disease therapeutics market, with a robust pipeline, strong analyst sentiment, and favorable market conditions, despite operational challenges and reimbursement complexities.

Alnylam Pharmaceuticals has announced its partnership with the Alliance for Genomic Discovery, a move expected to enhance the company’s clinical capabilities, pipeline diversification, and regulatory engagement, ultimately improving the efficacy and…

Alnylam Pharmaceuticals is accelerating towards profitability, bolstered by a strengthened capital structure and robust market momentum, driven by its innovative RNAi therapeutics and growing TTR franchise.

Alnylam Pharmaceuticals Inc. is experiencing promising growth, with recent successes in its Ambutra program and strong analyst ratings, despite a setback in a trial for its hypertension RNAi drug.

Alnylam Pharmaceuticals’ stock price is on a rollercoaster ride, but its financial woes, including a negative price-to-earnings ratio and overvalued price-to-book ratio, raise concerns about the company’s long-term prospects.

Alnylam Pharmaceuticals presented advancements in RNAi therapeutics for cardiovascular disease at the European Society of Cardiology 2025 Congress.